The News Review:
- The thoughts and methods for clinical research on acupuncture…
- Q3 2007 NRTHSTAR NEURSCIENCE INC Earnings Conference Call – Final.
- Expression Analysis Selected to Provide Illumina Genotyping Services…
- Human Genome Sciences Presents New Data Showing Anti Tumor Activity…
- New center to lead international muscular dystrophy research effort
The thoughts and methods for clinical research on acupuncture…
ProHealth – Oct 25, 2007
* Such aspects as case selection point selection and therapeutic assessment are also discussed in the present paper. Source: Journal of Traditional Chinese Medicine. 2007 Sep;27(3):163-5. PMID: 17955647 by Yao R.
Q3 2007 NRTHSTAR NEURSCIENCE INC Earnings Conference Call – Final.
Free with registration – Fair Disclosure Wire – AccessMyLibrary.com – Oct 25, 2007
ur platform technology through a novel cortical stimulation system is based upon targeted electrical stimulation of the cortex the outermost layer of the brain. The various areas of the cortex control or influence many important neurological functions making the cortex a rich target for therapeutic stimulation. Northstar is built on a foundation of science clinical research and intellectual property development and we are excited to be on the doorstep of having clinical results from our EVEREST pivotal trial. In the year and a half since we’ve become a public company we have effectively executed on our strategic plan and have brought our stroke recovery program to this important juncture while simultaneously making advances in three additional. CPYRIGHT 2007 Voxant Inc.
Expression Analysis Selected to Provide Illumina Genotyping Services…
carolinanewswire.com – Oct 25, 2007
Initial studies will rely on Illumina’s Human 1M DNA Analysis BeadChip which can interrogate more than one million genetic markers per sample. The SAEC is an international collaborative effort between the US Food and Drug Administration (FDA) several pharmaceutical companies and academia to identify genetic biomarkers that may predict which individuals are at risk for drug-related adverse events. In September 2007 the group announced that its first project will focus on liver toxicity using samples provided by DILIGEN and EUDRAGENE two European clinical research networks. “The SAEC is pleased to initiate services with Expression Analysis” said Arthur Holden Chairman of the SAEC. “The Scientific Management Committee under the leadership of Eric Lai [GSK] and Duncan McHale [Pfizer] independently evaluated many competing proposals and selected Expression Analysis based on its extensive “quality system” and service track record. The Committee also appreciated Expression Analysis’ ability to offer analytical services on a variety of genomic platforms in a “good laboratory practices environment”. ” “We are delighted to assist our pharmaceutical clients in generating pre-competitive genomic data which should lead to safer and more efficacious drugs” said Steve McPhail President and CE of Expression Analysis… “The SAEC recognized the value Expression Analysis provides and we are happy to contribute to this important effort. ” Expression Analysis achieved Illumina CsPR certification for both Infinium genotyping and whole-genome expression profiling earlier this year. In addition to offering Illumina BeadChip® services the company performs Affymetrix GeneChip® Luminex xMAP® and Applied Biosystems’ TaqMan® assays for clinical trials and clinical research in a regulatory compliant (GLP and CLIA) environment. About Expression Analysis Inc. Expression Analysis Inc. expressionanalysis.
Human Genome Sciences Presents New Data Showing Anti Tumor Activity…
Medical News Today – Medical News Today (press release) – Oct 25, 2007
The pharmacokinetics of HGS-ETR2 were not influenced by the chemotherapeutic agents nor did HGS-ETR2 affect the pharmacokinetics of gemcitabine doxorubicin or irinotecan. Further studies of HGS-ETR2 in combination with chemotherapy are warranted. “The results of the Phase 1b study of HGS-ETR2 show that it is well tolerated and can be repetitively administered in combination with standard chemotherapy agents in patients with a variety of advanced solid malignances” said Norma Lynn Fox Ph. Senior Director Clinical Research HGS. “We were encouraged by the observation of objective responses in two patients and stable disease in more than 20 patients a number of whom remained on treatment for more than five months before progression of disease. ” About the Preclinical Results in Cholangiocarcinoma Results were also presented from preclinical studies that evaluated the ability of HGS-ETR1 and HGS-ETR2 to kill cancer cells and inhibit tumor growth as single agents and in combination with chemotherapy agents: cisplatin gemcitabine or 5-fluorouracil.
New center to lead international muscular dystrophy research effort
eurekalert.org – Oct 25, 2007
He is also a major donor and supporter of the New York City Police Foundation and Good Shepherd Service and is a board member or Farm Aid a non-profit organization working to promote a strong and sustainable family farm-based system of agriculture throughout the country. “I have a personal family connection to FSHD so I know the impact it has on families throughout the United States and the world” said Fields. “The University of Rochester has long been a leader in muscular dystrophy research so they were a natural fit to establish a center to focus on genetic and clinical research to FSHD patients. I see this gift as a significant step in giving this disease the medical attention it deserves and hope that the Fields Center will be a center for leadership and innovation in the field for many years to come. FSHD is one of the more common forms of muscular dystrophy. Most symptoms do not appear until the teen years but the disease does also appear albeit more rarely in very young children and infants. The condition which is genetic in origin is characterized by a progressive weakness of muscles starting in the face shoulder blades and upper arms.
